MapLight Therapeutics (MPLT) Long-Term Investments (2024 - 2026)
MapLight Therapeutics (MPLT) posted Long-Term Investments of $148.0 million for Q4 2025, up 1200.47% sequentially from $11.4 million in Q4 2024, and up 1200.47% YoY from $11.4 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Long-Term Investments (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Long-Term Investments for 2 years, with the latest figure at $148.0 million in Q4 2025.
- Quarterly Long-Term Investments rose 1200.47% year-over-year to $148.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $148.0 million (up 1200.47% YoY) and the FY2025 annual result came in at $148.0 million, up 1200.47% from the prior year.
- Long-Term Investments improved to $148.0 million in Q4 2025 per MPLT's latest filing, from $11.4 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $148.0 million in Q4 2025 and troughed at $11.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | 46.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.62 Mn |
| Dec 31, 2025 | 147.99 Mn |
| Dec 31, 2024 | 11.38 Mn |